Literature DB >> 15900604

International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising.

Susan S Devesa1, Freddie Bray, A Paloma Vizcaino, D Max Parkin.   

Abstract

Lung cancer rates have peaked among men in many areas of the world, but rates among women continue to rise. Most lung cancers are squamous cell carcinoma, small cell carcinoma, or adenocarcinoma; trends vary according to type. We compiled population-based morphology-specific incidence data from registries contributing to the International Agency for Research on Cancer (IARC) databases. Unspecified cancers and carcinomas were reallocated based on a registry, time period, sex and age group-specific basis. Where available, data from several registries within a country were pooled for analysis. Rates per 100,000 person-years for 1980-1982 to 1995-1997 were age-adjusted by the direct method using the world standard. Squamous cell carcinoma rates among males declined 30% or more in North America and some European countries while changing less dramatically in other areas; small cell carcinoma rates decreased less rapidly. Squamous and small cell carcinoma rates among females generally rose, with the increases especially pronounced in the Netherlands and Norway. In contrast, adenocarcinoma rates rose among males and females in virtually all areas, with the increases among males exceeding 50% in many areas of Europe; among females, rates also rose rapidly and more than doubled in Norway, Italy and France. Rates of all lung cancer types among women and adenocarcinoma among men continue to rise despite declining cigarette use in many Western countries and shifts to filtered/low-tar cigarettes. Renewed efforts toward cessation and prevention are mandatory to curb the prevalence of cigarette smoking and to reduce lung cancer rates eventually.

Entities:  

Mesh:

Year:  2005        PMID: 15900604     DOI: 10.1002/ijc.21183

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  259 in total

1.  Variation in TP63 is associated with lung adenocarcinoma susceptibility in Japanese and Korean populations.

Authors:  Daiki Miki; Michiaki Kubo; Atsushi Takahashi; Kyong-Ah Yoon; Jeongseon Kim; Geon Kook Lee; Jae Ill Zo; Jin Soo Lee; Naoya Hosono; Takashi Morizono; Tatsuhiko Tsunoda; Naoyuki Kamatani; Kazuaki Chayama; Takashi Takahashi; Johji Inazawa; Yusuke Nakamura; Yataro Daigo
Journal:  Nat Genet       Date:  2010-09-26       Impact factor: 38.330

2.  A Phase I Study of Light Dose for Photodynamic Therapy Using 2-[1-Hexyloxyethyl]-2 Devinyl Pyropheophorbide-a for the Treatment of Non-Small Cell Carcinoma In Situ or Non-Small Cell Microinvasive Bronchogenic Carcinoma: A Dose Ranging Study.

Authors:  Samjot Singh Dhillon; Todd L Demmy; Sai Yendamuri; Gregory Loewen; Chukwumere Nwogu; Michele Cooper; Barbara W Henderson
Journal:  J Thorac Oncol       Date:  2015-12-22       Impact factor: 15.609

Review 3.  Epidermal growth factor receptor in non-small cell lung cancer.

Authors:  Charles N Prabhakar
Journal:  Transl Lung Cancer Res       Date:  2015-04

4.  Tumor Budding Correlates With the Protumor Immune Microenvironment and Is an Independent Prognostic Factor for Recurrence of Stage I Lung Adenocarcinoma.

Authors:  Kyuichi Kadota; Yi-Chen Yeh; Jonathan Villena-Vargas; Leonid Cherkassky; Esther N Drill; Camelia S Sima; David R Jones; William D Travis; Prasad S Adusumilli
Journal:  Chest       Date:  2015-09       Impact factor: 9.410

Review 5.  It's all about sex: gender, lung development and lung disease.

Authors:  Michelle A Carey; Jeffrey W Card; James W Voltz; Samuel J Arbes; Dori R Germolec; Kenneth S Korach; Darryl C Zeldin
Journal:  Trends Endocrinol Metab       Date:  2007-08-30       Impact factor: 12.015

6.  Association of cigarette smoking with the expression of nuclear survivin in pathological Stage IA lung adenocarcinomas.

Authors:  Hiroshi Hirano; Hajime Maeda; Yukiyasu Takeuchi; Yoshiyuki Susaki; Ryoji Kobayashi; Akio Hayashi; Naoko Ose; Yukie Nakazawa; Toshihiko Yamaguchi; Soichiro Yokota; Masahide Mori
Journal:  Med Mol Morphol       Date:  2013-11-09       Impact factor: 2.309

Review 7.  Epidemiology of lung cancer.

Authors:  Carole A Ridge; Aoife M McErlean; Michelle S Ginsberg
Journal:  Semin Intervent Radiol       Date:  2013-06       Impact factor: 1.513

8.  Overexpression of LAPTM4B is correlated with tumor angiogenesis and poor prognosis in non-small cell lung cancer.

Authors:  Han Tang; Hui Tian; Weiming Yue; Lin Li; Shuhai Li; Cun Gao; Libo Si; Lei Qi; Ming Lu
Journal:  Med Oncol       Date:  2014-05-11       Impact factor: 3.064

Review 9.  Tumour suppressor HLJ1: A potential diagnostic, preventive and therapeutic target in non-small cell lung cancer.

Authors:  Meng-Feng Tsai; Chi-Chung Wang; Jeremy Jw Chen
Journal:  World J Clin Oncol       Date:  2014-12-10

10.  Procedures for risk-stratification of lung cancer using buccal nanocytology.

Authors:  H Subramanian; P Viswanathan; L Cherkezyan; R Iyengar; S Rozhok; M Verleye; J Derbas; J Czarnecki; H K Roy; V Backman
Journal:  Biomed Opt Express       Date:  2016-08-31       Impact factor: 3.732

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.